000169971 001__ 169971
000169971 005__ 20240229133701.0
000169971 0247_ $$2doi$$a10.1016/j.yexmp.2021.104668
000169971 0247_ $$2pmid$$apmid:34302852
000169971 0247_ $$2ISSN$$a0014-4800
000169971 0247_ $$2ISSN$$a1096-0945
000169971 0247_ $$2altmetric$$aaltmetric:110167008
000169971 037__ $$aDKFZ-2021-01671
000169971 041__ $$aEnglish
000169971 082__ $$a610
000169971 1001_ $$aBajwa-Ten Broeke, Sanne W$$b0
000169971 245__ $$aThe coding microsatellite mutation profile of PMS2-deficient colorectal cancer.
000169971 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2021
000169971 3367_ $$2DRIVER$$aarticle
000169971 3367_ $$2DataCite$$aOutput Types/Journal article
000169971 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642169944_15951
000169971 3367_ $$2BibTeX$$aARTICLE
000169971 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169971 3367_ $$00$$2EndNote$$aJournal Article
000169971 500__ $$a#LA:F210# / 2021 Oct;122:104668
000169971 520__ $$aLynch syndrome (LS) is caused by a pathogenic heterozygous germline variant in one of the DNA mismatch repair (MMR) genes: MLH1, MSH2, MSH6 or PMS2. LS-associated colorectal carcinomas (CRCs) are characterized by MMR deficiency and by accumulation of multiple insertions/deletions at coding microsatellites (cMS). MMR deficiency-induced variants at defined cMS loci have a driver function and promote tumorigenesis. Notably, PMS2 variant carriers face only a slightly increased risk of developing CRC. Here, we investigate whether this lower penetrance is also reflected by differences in molecular features and cMS variant patterns. Tumor DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue cores or sections (n = 90). Tumors originated from genetically proven germline pathogenic MMR variant carriers (including 14 PMS2-deficient tumors). The mutational spectrum was analyzed using fluorescently labeled primers specific for 18 cMS previously described as mutational targets in MMR-deficient tumors. Immune cell infiltration was analyzed by immunohistochemical detection of T-cells on FFPE tissue sections. The cMS spectrum of PMS2-deficient CRCs did not show any significant differences from MLH1/MSH2-deficient CRCs. PMS2-deficient tumors, however, displayed lower CD3-positive T-cell infiltration compared to other MMR-deficient cancers (28.00 vs. 55.00 per 0.1 mm2, p = 0.0025). Our study demonstrates that the spectrum of potentially immunogenic cMS variants in CRCs from PMS2 gene variant carriers is similar to that observed in CRCs from other MMR gene variant carriers. Lower immune cell infiltration observed in PMS2-deficient CRCs could be the result of alternative mechanisms of immune evasion or immune cell exclusion, similar to those seen in MMR-proficient tumors.
000169971 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000169971 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169971 650_7 $$2Other$$aHNPCC
000169971 650_7 $$2Other$$aHereditary colorectal cancer
000169971 650_7 $$2Other$$aImmunology of cancer
000169971 650_7 $$2Other$$aMolecular pathways
000169971 7001_ $$0P:(DE-HGF)0$$aBallhausen, Alexej$$b1
000169971 7001_ $$0P:(DE-He78)07eef6d38a91f4642c810745c5bf5000$$aAhadova, Aysel$$b2$$udkfz
000169971 7001_ $$aSuerink, Manon$$b3
000169971 7001_ $$0P:(DE-He78)a7f54298fcba548e34453b02202e6519$$aBohaumilitzky, Lena$$b4$$udkfz
000169971 7001_ $$0P:(DE-He78)42ccf6cd47fe67a45f6c7ba82ef71cb4$$aSeidler, Florian$$b5$$udkfz
000169971 7001_ $$aMorreau, Hans$$b6
000169971 7001_ $$avan Wezel, Tom$$b7
000169971 7001_ $$0P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aKrzykalla, Julia$$b8$$udkfz
000169971 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b9$$udkfz
000169971 7001_ $$ade Miranda, Noel F$$b10
000169971 7001_ $$0P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f$$avon Knebel Doeberitz, Magnus$$b11$$udkfz
000169971 7001_ $$aNielsen, Maartje$$b12
000169971 7001_ $$0P:(DE-He78)028ee60cca729028708496826f077b58$$aKloor, Matthias$$b13$$eLast author$$udkfz
000169971 773__ $$0PERI:(DE-600)1466769-1$$a10.1016/j.yexmp.2021.104668$$gp. 104668 -$$p104668$$tExperimental and molecular pathology$$v122$$x0014-4800$$y2021
000169971 909CO $$ooai:inrepo02.dkfz.de:169971$$pVDB
000169971 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000169971 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)07eef6d38a91f4642c810745c5bf5000$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000169971 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7f54298fcba548e34453b02202e6519$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000169971 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)42ccf6cd47fe67a45f6c7ba82ef71cb4$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000169971 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000169971 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000169971 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000169971 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)028ee60cca729028708496826f077b58$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000169971 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000169971 9141_ $$y2021
000169971 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-26$$wger
000169971 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-26
000169971 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-26
000169971 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-26
000169971 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-26
000169971 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000169971 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-26
000169971 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-26
000169971 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000169971 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-26
000169971 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEXP MOL PATHOL : 2019$$d2021-01-26
000169971 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-26
000169971 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-26
000169971 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-26
000169971 9201_ $$0I:(DE-He78)F210-20160331$$kF210$$lAngewandte Tumorbiologie$$x0
000169971 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000169971 980__ $$ajournal
000169971 980__ $$aVDB
000169971 980__ $$aI:(DE-He78)F210-20160331
000169971 980__ $$aI:(DE-He78)C060-20160331
000169971 980__ $$aUNRESTRICTED